-
Researchers to present CV findings from SOUL trial of oral semaglutide in high-risk type 2 diabetes
Investigators, including John B. Buse, MD, PhD, will detail the key findings of a study to determine whether a new oral formulation of semaglutide is a safe and effective alternative to the injectable formulation.
-
Symposium will highlight major STRIDE forward in treating PAD alongside type 2 diabetes
Principal investigator Subodh Verma, MD, PhD, FRCSC, will share key results from a clinical trial using semaglutide in patients with type 2 diabetes and peripheral artery disease.
-
Panel to spotlight potential of continuous ketone monitoring
Just as continuous glucose monitoring is transforming diabetes care with improved glucose management, continuous ketone monitoring could dramatically improve patient outcomes. Experts, including Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD, will explain how.
-
MariTide investigators will review trial data for monthly obesity treatment
Among the panelists, Ania M. Jastreboff, MD, PhD, will discuss results for participants without type 2 diabetes, and Harold Bays, MD, will discuss results for participants with the disease.
-
Researchers to share PATHWEIGH ‘roadmap’ for implementing weight management processes into primary care
PATHWEIGH focuses on reducing excess body weight and weight-related medical complications by providing patients with highly individualized care based on their needs, access, and preferences.
-
Symposium will discuss QWINT results that could signal paradigm shift in basal insulin dosing
Chantal Mathieu, MD, PhD, and other researchers will explain the latest data from a series of pivotal trials on once-weekly insulin efsitora alfa.
-
Investigators will present findings from treatment phase of CATALYST trial
Researchers, including Vivian Fonseca, MD, will return to the Scientific Sessions with new data on mifepristone use to treat people with hypercortisolism and difficult-to-manage type 2 diabetes.
-
Session will explore the new frontier of adjunctive therapies in type 1 diabetes
Among the expert panelists, Klara R. Klein, MD, PhD, will explore the role of glucokinase activators in type 1 diabetes and the prevention of hypoglycemia.
Presenter Profiles
